✦ LIBER ✦

Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine

✍ Scribed by David Berd

Book ID: 117431291
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 55 KB
Volume: 21
Category: Article
ISSN: 0264-410X
DOI: 10.1016/s0264-410x(02)00601-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti-metastatic activity of hapten-modif

Anti-metastatic activity of hapten-modified autologous tumor cell vaccine in an animal tumor model

✍ Dorothy K. Sojka, Diana Felnerova, Margalit B. Mokyr 📂 Article 📅 2002 🏛 Springer-Verlag 🌐 English ⚖ 168 KB

Effect of the dose and composition of an

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses

✍ David Berd; Takami Sato; Michael J. Mastrangelo 📂 Article 📅 2002 🏛 Springer-Verlag 🌐 English ⚖ 137 KB

5290551 Treatment of melanoma with a vac

5290551 Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten: David Berd assigned to Thomas Jefferson University

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 90 KB

A novel role for autologous tumour cell

A novel role for autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma

✍ J.D. Geiger; P.D. Wagner; S. Shu; A.E. Chang 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 946 KB

533 POSTER Autologous large multivalent

533 POSTER Autologous large multivalent immunogen vaccine for the treatment of stage IV malignant melanoma and stage IV renal cell carcinoma

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 157 KB

A preclinical model to assess the antige

A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine

✍ Yoshihiko Hayashi; Dave S. B. Hoon; Leland J. Foshag; Min S. Park; Paul I. Teras 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 876 KB

Background. The authors have demonstrated that immunization with melanoma whole-cell vaccine (MCV) augments T-cell responses to melanoma and that cytotoxic T-cells (CTL) recognize allogeneic melanoma-bearing shared HLA-A antigens. A preclinical model was developed to assess CTL activation in vitro u